Abstract
© Springer International Publishing Switzerland 2016. Biomarkers have emerged as indispensable tools for diagnosis and prognosis in a variety of cardiovascular diseases, and several are now considered standard of care. New markers are constantly being developed, but very few are able to signifi- cantly improve upon already-established markers. ST2 is a marker of cardiomyocyte stress and fibrosis which provides incremental value to natriuretic peptides for risk stratification in heart failure. Based upon the totality of data, measurement of ST2 is now recommended for additive risk stratification in patients with acute or ambulatory heart failure in the 2013 ACCF/AHA Guidelines. Looking forward, ST2 levels may be useful for tailoring medical therapy and to predict ventricular reverse remodeling. This chapter provides an up-to-date overview of ST2 as a marker of heart failure, and provides illustrative clinical cases into the application of ST2 now and in the future.
| Original language | English |
|---|---|
| Title of host publication | Cardiac Biomarkers: Case Studies and Clinical Correlations |
| Pages | 251-268 |
| Number of pages | 17 |
| DOIs | |
| Publication status | Published - 1 Jan 2016 |
Keywords
- Biomarker ST2
- Biomarkers in heart failure
- Cardiomyocyte stress and fibrosis
- Heart failure biomarkers
- Risk prediction in chronic heart failure
- ST2 biomarker
